• Mashup Score: 0

    In her May 2023 Editor’s Corner, Brea Lipe, MD, discussed the dark side of chime ric antigen receptor (CAR) T-cell therapy in multiple myeloma (MM). Given their high and durable response rates, there has been much excitement around the use of idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), though various challenges have hindered widespread implementation of these therapies. Here, a reader continues the conversation, raising questions about whether patients with MM should

    Tweet Tweets with this article
    • Ide-cel and cilta-cel, two CAR T-cell therapies, have shown high response rates in patients; however, as the treatment landscape for #CAR T-cell therapy continues to change, discussions on navigating barriers to their widespread implementation remain key. https://t.co/GXsPKX0iNo

  • Mashup Score: 0

    Benjamin Schlechter, MD, Dana-Farber Cancer Institute, Boston, MA, comments on challenges in developing CAR T-cell therapies for solid tumors. Finding…

    Tweet Tweets with this article
    • 🎥@ben_schlechter of @DanaFarber highlights challenges in CAR T-cell therapies for solid tumors. Safe targets such as CLDN18.2 show promise, while established receptors like HER2 can cause severe toxicity: ➡️https://t.co/zndRFsBEWI⬅️ #ImmunoOnc #CAR-T #ASCO23 @ASCO

  • Mashup Score: 0
    Wolters Kluwer Health - 9 month(s) ago

    JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…

    Tweet Tweets with this article
    • #CAR-T therapies are used as third-line therapy for R/R #DLBCL, but some patients can't receive them. One therapy being evaluated glofitamab, an off-the-shelf bispecific antibody that targets malignant B cells while while engaging T cells. @PeterMacCC https://t.co/oHqING7bD9 https://t.co/MDNH8eO72G